Recent blog posts
NCT07685704 Tislelizumab stomach adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07685704 Tislelizumab stomach adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07685704 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07685938 Lisinopril Neoplasm of chest wall Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07685938 Lisinopril Neoplasm of chest wall Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07685938 clinical trial report covering Lisinopril, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07682961 Zinlirvimab HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07682961 Zinlirvimab HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07682961 clinical trial report covering Zinlirvimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07683000 Zinlirvimab HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07683000 Zinlirvimab HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07683000 clinical trial report covering Zinlirvimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262444 Fuzheng Tonglin Pills Prostatic Hyperplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262444 Fuzheng Tonglin Pills Prostatic Hyperplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262444 clinical trial report covering Fuzheng Tonglin Pills, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07684144 Maridebart Cafraglutide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07684144 Maridebart Cafraglutide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684144 clinical trial report covering Maridebart Cafraglutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07684235 Maridebart Cafraglutide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07684235 Maridebart Cafraglutide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684235 clinical trial report covering Maridebart Cafraglutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07685808 Olatorepatide Prediabetic State Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07685808 Olatorepatide Prediabetic State Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07685808 clinical trial report covering Olatorepatide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07684040 Adebrelimab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07684040 Adebrelimab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684040 clinical trial report covering Adebrelimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07684456 Utidelone HER2-negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07684456 Utidelone HER2-negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684456 clinical trial report covering Utidelone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07684287 Sirolimus Albumin-Bound Epithelioid Hemangioendothelioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07684287 Sirolimus Albumin-Bound Epithelioid Hemangioendothelioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684287 clinical trial report covering Sirolimus Albumin-Bound, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07683026 Golimumab Diabetes Mellitus, Type 1 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07683026 Golimumab Diabetes Mellitus, Type 1 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07683026 clinical trial report covering Golimumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →